Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It also offers dry powder inhaler products consisting of albuterol (APC-2000) for the treatment of bronchospasms; fluticasone (APC-4000) for the treatment of asthma; beclomethasone (APC-1000), a metered dose inhaler product for the asthma; and naloxone injection product candidates (APC-6000) for the treatment of opioid overdose. In addition, the company provides corticosteroids, hormone replacement therapies, hospital outsourcing products, injectables, urological preparations, ophthalmic preparations, topical compounds for pain, and men's and women's health products; and certain veterinary pharmaceutical products for animals. Adamis Pharmaceuticals Corporation is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-997-2400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.07 million
Profitability
Miscellaneous
Employees126
OptionableOptionable
Adamis Pharmaceuticals (NASDAQ:ADMP) Frequently Asked Questions
What is Adamis Pharmaceuticals' stock symbol?
Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."
How were Adamis Pharmaceuticals' earnings last quarter?
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) issued its quarterly earnings results on Friday, August, 10th. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.10. The specialty pharmaceutical company had revenue of $3.92 million for the quarter, compared to analyst estimates of $4.14 million. Adamis Pharmaceuticals had a negative return on equity of 87.64% and a negative net margin of 248.43%. View Adamis Pharmaceuticals' Earnings History.
When is Adamis Pharmaceuticals' next earnings date?
What price target have analysts set for ADMP?
4 brokers have issued 1 year price targets for Adamis Pharmaceuticals' stock. Their forecasts range from $2.50 to $10.00. On average, they expect Adamis Pharmaceuticals' stock price to reach $6.6250 in the next year. This suggests a possible upside of 111.7% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.
What is the consensus analysts' recommendation for Adamis Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Adamis Pharmaceuticals.
What are Wall Street analysts saying about Adamis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Adamis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned subsidiaries, Adamis Labs and Adamis Viral Therapies. Adamis Labs is a commercial stage specialty pharmaceutical company targeting high-prescribing physicians in the allergy, respiratory and pediatric medicine market segments. To complement and add to the sales efforts of Adamis Labs, Adamis Viral Therapies is focused on the development of patented, highly-valued proprietary vaccine technology that Adamis believes has the potential to prevent or treat infections such as influenza or chronic hepatitis. Adamis also provides packaging for pharmaceutical and nutraceutical products. The company is headquartered in Del Mar, California. " (1/14/2019)
- 2. Maxim Group analysts commented, "The PDUFA date for Symjepi jr. (0.15mg) is approaching on 9/27/18, we expect a positive response from the FDA. Symjepi (0.3mg & 0.15mg) is partnered to Sandoz-Novartis (NVS – NR). Our expectation is that Sandoz will launch both Symjepi products sometime in the second half following low-dose approval (though precise timing has not been announced)." (9/12/2018)
- 3. HC Wainwright analysts commented, "EpiPen as an Exchange NASDAQ Value (M) $65.4 Market Cap (M) $101 Shares Outstanding (M) 45.1 3 Interest (M) 3.55 Cash (M) $37.9 Total Debt (M) $2.3 Cash balances and share count are projected based on 3Q18 capital raise." (8/23/2018)
Has Adamis Pharmaceuticals been receiving favorable news coverage?
Media coverage about ADMP stock has trended neutral this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of 0.3 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the next several days.
Who are some of Adamis Pharmaceuticals' key competitors?
Some companies that are related to Adamis Pharmaceuticals include Urogen Pharma (URGN), Lexicon Pharmaceuticals (LXRX), Karyopharm Therapeutics (KPTI), Akorn (AKRX), AMAG Pharmaceuticals (AMAG), ChemoCentryx (CCXI), Flexion Therapeutics (FLXN), Prothena (PRTA), Eidos Therapeutics (EIDX), Aurinia Pharmaceuticals (AUPH), BioSpecifics Technologies (BSTC), GlycoMimetics (GLYC), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL) and Zymeworks (ZYME).
Who are Adamis Pharmaceuticals' key executives?
Adamis Pharmaceuticals' management team includes the folowing people:
- Mr. Richard C. Williams, Chairman & Consultant (Age 75)
- Dr. Dennis J. Carlo, Pres, CEO & Director (Age 76)
- Mr. Robert O. Hopkins, VP of Fin., CFO & Sec. (Age 59)
- Mr. David J. Marguglio, Sr. VP, Chief Bus. Officer & Director (Age 49)
- Mr. Robert B. Rothermel, Consultant & Director (Age 75)
Who are Adamis Pharmaceuticals' major shareholders?
Adamis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.04%), Geode Capital Management LLC (0.64%), Northern Trust Corp (0.35%), Raymond James & Associates (0.10%), Barclays PLC (0.10%) and Oppenheimer & Co. Inc. (0.04%). View Institutional Ownership Trends for Adamis Pharmaceuticals.
Which major investors are selling Adamis Pharmaceuticals stock?
Which major investors are buying Adamis Pharmaceuticals stock?
ADMP stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Barclays PLC, Geode Capital Management LLC, Raymond James & Associates, Oppenheimer & Co. Inc., Cambridge Investment Research Advisors Inc. and Jane Street Group LLC. View Insider Buying and Selling for Adamis Pharmaceuticals.
How do I buy shares of Adamis Pharmaceuticals?
Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Adamis Pharmaceuticals' stock price today?
One share of ADMP stock can currently be purchased for approximately $3.13.
How big of a company is Adamis Pharmaceuticals?
Adamis Pharmaceuticals has a market capitalization of $148.02 million and generates $13.07 million in revenue each year. The specialty pharmaceutical company earns $-25,530,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Adamis Pharmaceuticals employs 126 workers across the globe.
What is Adamis Pharmaceuticals' official website?
How can I contact Adamis Pharmaceuticals?
Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]
MarketBeat Community Rating for Adamis Pharmaceuticals (NASDAQ ADMP)
MarketBeat's community ratings are surveys of what our community members think about Adamis Pharmaceuticals and other stocks. Vote "Outperform" if you believe ADMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
